The assistant professor of BMT and cellular therapy discussed updated safety and efficacy data on CD22 CAR T-cell therapy.
The hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.
The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s efforts to introduce new technologies for improving cell therapy development and manufacturing.
The director of clinical research at Sierra Eye Associates discussed 4D Molecular Therapeutics’ plans for 4D-150 in both wet AMD and diabetic macular edema.
The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.
The assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.
The hematologist at Ohio State University Comprehensive Cancer Center–The James discussed utilization rates of autologous stem cell transplant in patients with mantle cell lymphoma.
The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.
The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.
Michael Singer, MD, PhD, cofounder and chief scientific officer of Cartesian Therapeutics, discussed the company’s lead candidate, Descartes-08.
Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.
The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
The pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.
Lineage Cell Therapeutics CEO Brian Culley shares a clinical trial update on their leading cell therapy candidate and discusses the important role of the FDA as more players enter the cell and gene therapy space.
The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.
James Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
The chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.
The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
The associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center discussed Sangamo Therapeutics’ gene therapy, ST-920, and the phase 2 STAAR clinical trial.
Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
The child neurologist and neuromuscular physician at Virginia Commonwealth University also discussed the session she chaired at the 2023 MDA Clinical and Scientific Conference.
The chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.
Pam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access to advanced care.
The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.
The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.
The chief scientific officer at Candel Therapeutics discussed late-breaking data presented at ASGCT 2023.